A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Cannabidiol (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- 23 Jan 2024 Planned End Date changed from 1 Aug 2022 to 30 Jun 2025.
- 23 Jan 2024 Planned primary completion date changed from 1 May 2022 to 31 Dec 2024.
- 26 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Aug 2022.